Patheon's CEO Speaks

Roth, Gil Y.
May 2012
Contract Pharma;May2012, Vol. 14 Issue 4, p104
Trade Publication
An interview with Jim Mullen, Patheon Inc.'s chief executive officer (CEO), is presented. He discusses the economic trends on the outsourcing processes at the pharmaceutical industry. He also tackles strategic partnerships of business enterprises at the industry and notes his administration at Biogen Idec.


Related Articles

  • Nanotechnology Will Deliver Medicines Where They Need to Be. Weeks, Katie // San Diego Business Journal;11/20/2006, Vol. 27 Issue 47, p4 

    The article reports on the contribution and achievement of Bill Rastetter in the field of biotechnology industry in the U.S. Rastetter was responsible for the merger of Biogen Idec Inc., which is now the third largest biotechnology company in the world. He was the chairman of the board at Biogen...

  • Industry Audit Winner Outtakes: Blockbusters, Indoor Golf, and the Velvet Underground.  // Pharmaceutical Executive;Sep2011, Vol. 31 Issue 9, p114 

    The article presents information on pharmaceutical companies including Novo Nordisk, Gilead Sciences Inc., Celgene, Biogen Idec Inc., and AstraZeneca PLC. Details on their blockbusters, chief executive officers (CEOs) since 2001, dividends in 2010, headquarter (HQ) local flavor, and employee...

  • Biogen Idec set on developing pipeline of drugs.  // PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p14 

    Reports that Biogen Idec Inc. CEO Jim Mullen has dismissed claims that its recent merger was set upon achieving economies of scale. Aim of the company to develop a pipeline of drugs previously unobtainable to each party; Potentials of the company to develop molecule drugs; Amount of sales...

  • Biogen Restructuring Unlikely To Hit Venture Arm, Incubator. Boggs, Jennifer // BioWorld Insight;11/15/2010, Vol. 18 Issue 46, p3 

    The article presents the author's insights on the plan of chief executive officer (CEO) George Scango of Biogen Idec Inc. to focus on neurology, abandoning cardiology and oncology. The author says that most analysts view the restructuring plan as a good move, but some notes on the risk on...

  • New Biogen CEO Scangos to Crack Down on R&D Spending. Boggs, Jennifer // BioWorld Today;7/2/2010, Vol. 21 Issue 127, p1 

    The article highlights the plans of George Scangos as chief executive officer of Biogen Idec Inc. According to the author, Scangos will be facing tough problems in handling the company. When asked about his plans, Scangos revealed that he will focus on enhancing the company's commercial...

  • Newsmakers: Peter Bigelow. Roth, Gil Y. // Contract Pharma;Jan/Feb2011, Vol. 13 Issue 1, p48 

    An interview with Peter Bigelow, interim chief executive officer (CEO) of Patheon Inc., is presented. He discusses how the transition in their company was going and praises how the team supported him in his position as CEO. He mentions the importance of their strong Pharmaceutical Development...

  • LigoCyte, Biogen Partner On Inflammatory Diseases.  // Bioworld Week;9/24/2007, Vol. 15 Issue 39, p3 

    The article reports on the partnership between LigoCyte Pharmaceuticals Inc. and Biogen Idec Inc. to develop therapies to treat chronic inflammatory disease in the U.S. The firms will develop products that target CD103, a unique alphaEbeta7 integrin that has been implicated in the activation,...

  • Can Multivariate Partnerships Streamline Drug Development?  // Contract Pharma;Jun2014, Vol. 16 Issue 5, p34 

    An interview with Stacie Yonkin, senior vice president and managing director, and Paula Brown Stafford, president of Clinical Development, at biopharmaceutical development provider Quintiles is presented. Topics discussed include the five-year strategic clinical development pact and multiyear...

  • Biogen Idec: PDL deal is antibodies' guess.  // PharmaWatch: CNS;Sep2005, Vol. 4 Issue 9, p4 

    This article reports that Biogen Idec Inc. has entered into a collaboration agreement with Protein Design Labs Inc. (PDL) for three antibody products currently in phase II clinical trials. Although the deal could prove lucrative for PDL. Biogen Idec is paying PDL $40 million upfront under the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics